Idexx Laboratories (IDXX) EBT (2009 - 2026)

Idexx Laboratories (IDXX) has reported EBT for 18 consecutive years, with $355.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT rose 14.63% year-over-year to $355.4 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 21.8% YoY), while the FY2025 annual figure was $1.3 billion, up 19.31% from the prior year.
• EBT came in at $355.4 million for Q1 2026 at Idexx Laboratories, up from $307.0 million in the prior quarter.
• The five-year high for EBT was $362.4 million in Q2 2025, with the low at $171.1 million in Q2 2022.
• Average EBT over 5 years is $277.1 million, with a median of $267.9 million recorded in 2023.
• Across the five-year window, EBT tumbled 32.04% in 2022 and soared 67.13% in 2023, its largest moves.
• Year by year, EBT stood at $213.2 million in 2022, then climbed by 12.41% to $239.7 million in 2023, then increased by 6.98% to $256.4 million in 2024, then advanced by 19.73% to $307.0 million in 2025, then gained by 15.79% to $355.4 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $355.4 million, $307.0 million, and $344.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.